Novel systemic drugs for cutaneous T-cell lymphoma.
For the last few years new therapeutic options for primary cutaneous T-cell lymphoma (CTCL) have been recently introduced into clinical trials, particularly for patients with advanced stage and refractory disease. Systemic treatment uses biological response modifiers, such as fusion molecules, rexinoids, interferons as well as monoclonal antiobodies, and new antiproliferative drugs, such as histone deacetylase inhibitors, proteasome inhibitors or forodesine. This review focuses on recent advances in the development of systemic agents for CTCL including both novel patented compounds and novel therapeutic protocol of intervention.
Department of Hematology, Medical University of Lodz, Copernicus Memorial Hospital, 93-513 Lodz, Ciolkowskiego 2, Poland.
Ewa
E
Lech-Maranda
Ewa
E
Robak
Tadeusz
T
Robak
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D015507:Drugs, Investigational / Q000008:administration & dosage*; D056572:Histone Deacetylase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage / Q000627:therapeutic use; D007275:Injections, Intravenous; D016399:Lymphoma, T-Cell / Q000188:drug therapy*; D008954:Models, Biological; D012878:Skin Neoplasms / Q000188:drug therapy*
D000970:Antineoplastic Agents; D015507:Drugs, Investigational; D056572:Histone Deacetylase Inhibitors; D007155:Immunologic Factors